IRE1a-Induced FilaminA Phosphorylation Enhances Migration of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients
Cells · 2023
DOI: 10.3390/cells12151935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Francesco Da Ros und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Unit, Department of Research and Advance Cancer Diagnostic, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Multiple Myeloma, Filamins, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Finchè ci siete voi ci sono anche io, Alleanza Contro il Cancro, Associazione Italiana Contro Leucemie Linfomi e Mieloma (AIL).
Abstract (Originalsprache)
Multiple myeloma (MM) is an aggressive malignancy that shapes, during its progression, a pro-tumor microenvironment characterized by altered protein secretion and the gene expression of mesenchymal stem cells (MSCs). In turn, MSCs from MM patients can exert an high pro-tumor activity and play a strong immunosuppressive role. Here, we show, for the first time, greater cell mobility paralleled by the activation of FilaminA (FLNA) in MM-derived MSCs, when compared to healthy donor (HD)-derived MSCs. Moreover, we suggest the possible involvement of the IRE1a-FLNA axis in the control of the MSC migration process. In this way, IRE1a can be considered as a good target candidate for MM therapy, considering its pro-survival, pro-osteoclast and chemoresistance role in the MM microenvironment. Our results suggest that IRE1a downregulation could also interfere with the response of MSCs to MM stimuli, possibly preventing cell–cell adhesion-mediated drug resistance. In addition, further investigations harnessing IRE1a-FLNA interaction could improve the homing efficiency of MSC as cell product for advanced therapy applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cell Unit, Department of Research and Advance Cancer Diagnostic, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
- Department of Life Sciences, University of Trieste, 34151 Trieste, Italy.
- Oncohematology and Cell Therapy Unit, Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
ORCID-Profile: Francesco Da Ros, Elisabetta Lombardi, Francesco Agostini, Maurizio Rupolo, Mario Mazzucato
Förderung
- Finchè ci siete voi ci sono anche io
- Alleanza Contro il Cancro
- Associazione Italiana Contro Leucemie Linfomi e Mieloma (AIL)
- “Ottone Zanolin e Elena Dametto” Associazione ONLUS
Zitieren
APA
Da Ros, F., Kowal, K., Vicinanza, C., Lombardi, E., Agostini, F., Ciancia, R., Rupolo, M., Durante, C., Michieli, M., & Mazzucato, M. (2023). IRE1a-Induced FilaminA Phosphorylation Enhances Migration of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients. Cells. https://doi.org/10.3390/cells12151935
Vancouver
Da Ros F, Kowal K, Vicinanza C, Lombardi E, Agostini F, Ciancia R, et al. IRE1a-Induced FilaminA Phosphorylation Enhances Migration of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients. Cells. 2023. doi:10.3390/cells12151935
BibTeX
@article{DaRos2023,
author = {Da Ros, Francesco and Kowal, Kinga and Vicinanza, Carla and Lombardi, Elisabetta and Agostini, Francesco and Ciancia, Rosanna and Rupolo, Maurizio and Durante, Cristina and Michieli, Mariagrazia and Mazzucato, Mario},
title = {IRE1a-Induced FilaminA Phosphorylation Enhances Migration of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12151935}
}
EUVIMED